Page 123 - 《中国药房》2023年9期
P. 123

1 例藤黄微球菌致感染性心内膜炎合并重症肺炎的药学监护
                                                                                                          Δ


                                               #
                *
          王司允 ,陈俊俊,朱玉辉,李 馨,张新茹(吉林大学第二医院药学部,长春 130041)
          中图分类号  R969.3      文献标志码  A      文章编号  1001-0408(2023)09-1137-05
          DOI  10.6039/j.issn.1001-0408.2023.09.21

          摘  要  目的  为藤黄微球菌致感染性心内膜炎(IE)合并重症肺炎的抗感染药物治疗及药学监护提供思路和用药参考。方法  临
          床药师全程参与1例藤黄微球菌致IE合并重症肺炎患者的治疗过程,所有抗感染治疗方案与调整均为临床医师邀请临床药师会
          诊后共同协商确定。方案实施后由临床药师从最适宜治疗药物、利用稳态谷浓度和内生肌酐清除率等参数调整万古霉素剂量、监
          测肾功能及药物不良反应等方面对治疗的有效性和安全性进行药学监护。结果  藤黄微球菌致IE患者经手术和术后足疗程的抗
          菌药物治疗后治愈,重症肺炎好转,原发病及治疗药物引起的肾功能下降有所恢复;临床药师通过协助临床医师制定治疗方案、实
          施药学监护,保证了患者抗感染治疗的效果,避免了患者进一步的肾损伤,解决了头孢哌酮舒巴坦药物热的问题。结论  藤黄微球
          菌致IE病情较重,可选万古霉素联合利福平治疗,治疗过程中应注意监测患者的肾功能,及时调整万古霉素剂量或更换药物;临
          床药师提供的抗感染药学监护,保障了患者抗感染治疗的有效性和安全性,避免了严重不良反应的发生。
          关键词  藤黄微球菌;感染性心内膜炎;重症肺炎;药学监护;临床药师

          Pharmaceutical  care  for  a  case  of  infective  endocarditis  caused  by  Micrococcus  luteus  complicated  with
          severe pneumonia
          WANG Siyun,CHEN Junjun,ZHU Yuhui,LI Xin,ZHANG Xinru(Dept.  of  Pharmacy,  the  Second  Hospital  of
          Jilin University, Changchun 130041, China)

          ABSTRACT   OBJECTIVE  To  provide  ideas  and  reference  for  the  treatment  and  pharmaceutical  care  of  infective  endocarditis
         (IE)  caused  by  Micrococcus  luteus  complicated  with  severe  pneumonia.  METHODS  The  clinical  pharmacist  participated  in  the
          treatment  of  a  patient  with  IE  caused  by  M.  luteus  complicated  with  severe  pneumonia;  all  anti-infective  treatment  plans  were
          agreed  upon  after  the  doctor  invited  the  clinical  pharmacist  for  consultation.  After  the  implementation  of  the  plan,  the  clinical
          pharmacist  conducted  pharmaceutical  care  of  effectiveness  and  safety  for  the  plan,  including  adopting  suitable  drug,  adjusting  the
          dose  of  vancomycin  by  using  parameters  such  as  steady-state  valley  concentration  and  creatinine  clearance  rate,  monitoring  renal
          function and adverse drug reactions. RESULTS IE caused by M. luteus was cured after surgery and full treatment with anti-bacterial
          drugs,  the  severe  pneumonia  was  improved,  and  the  decline  of  renal  function  caused  by  drugs  and  the  primary  disease  were
          recovered;  clinical  pharmacists  had  ensured  the  effect  of  anti-infection  treatment  by  assisting  in  the  formulation  of  treatment  plans
          and the implementation of pharmaceutical care, avoiding further renal damage and solving the problem of cefoperazone sulbactam-
          related  drug  fever.  CONCLUSIONS  IE  caused  by  M.  luteus  is  relatively  serious,  and  the  treatment  drug  can  be  vancomycin  and
          rifampicin. During the treatment, it is necessary to monitor the renal function, and adjust the dose of vancomycin or change other
          drugs;  anti-infection  pharmaceutical  care  provided  by  clinical  pharmacists  can  guarantee  the  effectiveness  and  safety  of  anti-
          infection plan, and avoid the occurrence of severe adverse drug reactions.
          KEYWORDS    Micrococcus luteus; infective endocarditis; severe pneumonia; pharmaceutical care; clinical pharmacist



              感染性心内膜炎(infective endocarditis,IE)合并重          IE患者。该患者术后在院治疗期间合并重症肺炎,出现
          症肺炎是临床较为难治的重症感染,通常需要多学科协                           了严重肾损伤,并发生了抗菌药物不良反应。藤黄微球
          作诊疗,给予足量抗菌药物治疗 4~6 周或以上,严重者                        菌是一种临床罕见的致病菌,属于细菌微球菌科微球菌
          需要进行瓣膜置换等手术治疗。笔者作为临床药师在                            属,是一种接触酶阳性、不分解葡萄糖的革兰氏阳性球
                                                               [1]
                                                             菌 。该菌主要分布于泥土、水等自然环境,以及健康人
          吉林大学第二医院(以下简称“本院”)心血管外科实践
                                                             体、动物皮肤表面或人体口腔,一般不致病,但仍可作为
          时监护了 1 例由非典型致病菌——藤黄微球菌引起的
                                                             条件致病菌,引起伤口等局部组织感染。该菌导致的严
             Δ 基金项目 吉林省高教科研课题(No. JGJX2020D8)                重感染(如IE)较为罕见 ,国内未见报道,国外仅有少量
                                                                                 [2]
             *第一作者 药师,硕士。研究方向:抗感染药物治疗、肠外肠内营                  报道,且均涉及假体植入           [3―4] 或免疫缺陷  [5―6] 。本文对笔
          养支持治疗。电话:0431-81159212。E-mail:wangsy2813@163.com
                                                             者监护的 1 例藤黄微球菌致 IE 合并重症肺炎患者的诊
             # 通信作者 副主任药师,博士。研究方向:心血管疾病药物治疗、
          抗感染药物治疗。电话:0431-81159212。E-mail:xinru@jlu.edu.cn   断和治疗过程进行分析,以期为此类患者治疗及药学监


          中国药房  2023年第34卷第9期                                                China Pharmacy  2023 Vol. 34  No. 9    · 1137 ·
   118   119   120   121   122   123   124   125   126   127   128